Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening
Gabriele Picco(Wellcome Sanger Institute), Mathew J. Garnett(Wellcome Sanger Institute), Fengtang Yang(Shandong University of Technology), Luz García‐Alonso(Wellcome Sanger Institute), Angela Matchan(Wellcome Sanger Institute), Fiona M. Behan(Age UK), Elisabeth Chen(Wellcome Sanger Institute), Beiyuan Fu(Wellcome Sanger Institute), Cyril H. Benes(Harvard University), Graham R. Bignell(Lund University), Emanuel Gonçalves(European Bioinformatics Institute), Ruby Banerjee(Wellcome Sanger Institute), Euan A. Stronach(Age UK), Ultan McDermott(AstraZeneca (United Kingdom)), Francesco Iorio(Human Technopole), Elizabeth Anderson(Wellcome Sanger Institute), David J. Dow(GlaxoSmithKline (United Kingdom)), Kosuke Yusa(Kyoto University), Adam P. Butler(Wellcome Sanger Institute), Julio Sáez-Rodríguez(European Bioinformatics Institute)
Cited by 134
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Drug repurposing: progress, challenges and recommendations
|Nature Reviews Drug Discovery|2018|4.6k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Patterns of somatic mutation in human cancer genomes
|Nature|2007|3.1k